First CVD Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) study also found a modest benefit for weight control, and no increase of risk for hypoglycemia or pancreatic injury. There was no increased risk for cardiovascular death, heart attack, stroke, unstable angina or heart failure in people with type 2 diabetes. But no benefits either were found. Presented at the ADA Scientific Sessions June 2015